VistaGen Therapeutics - Stock Price History | VTGN

Historical daily share price chart and data for VistaGen Therapeutics since 2021 adjusted for splits. The latest closing stock price for VistaGen Therapeutics as of September 24, 2021 is 2.83.
  • The all-time high VistaGen Therapeutics stock closing price was 4.41 on October 04, 2016.
  • The VistaGen Therapeutics 52-week high stock price is 3.55, which is 25.4% above the current share price.
  • The VistaGen Therapeutics 52-week low stock price is 0.61, which is 78.4% below the current share price.
  • The average VistaGen Therapeutics stock price for the last 52 weeks is 2.08.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
VistaGen Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 0.6528 0.7500 1.9400 0.3163 1.9400 181.28%
2019 0.9757 1.5900 1.7600 0.2960 0.6897 -54.02%
2018 1.3909 1.1600 2.2400 0.8500 1.5000 34.72%
2017 1.8736 3.7325 3.7325 0.7200 1.1134 -70.15%
2016 3.7662 4.1085 4.4100 2.8652 3.7300 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.569B $0.001B
VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71